Cobimetinib

CAS: 934660-93-2

Indication:  For the treatment of adults with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib. It is also indicated for the treatment of adults with histiocytic neoplasms.